AstraZeneca
British-Swedish pharmaceutical company
AZN London SE · home listing
AZN NYSE
AZN Nasdaq Stockholm
ISIN GB0009895292 SEC CIK 901832 LEI PY6ZZQWO2IZFZC3IOL08
Follow AstraZeneca
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $58.7B | $10.2B |
| FY24 | $54.1B | $7B |
| FY23 | $45.8B | $6B |
| FY22 | $44.4B | $3.3B |
| FY21 | $37.4B | $112M |
| FY20 | $26.6B | $3.2B |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 81.9% | 23.4% | 17.4% |
| FY24 | 81.1% | 18.5% | 13% |
| FY23 | 82% | 17.9% | 13% |
| FY22 | 72.1% | 8.5% | 7.4% |
| FY21 | 66.8% | 2.8% | 0.3% |
| FY20 | 80.1% | 19.4% | 12% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $11.8B |
| FY24 | $9.9B |
| FY23 | $9B |
| FY22 | $8.7B |
| FY21 | $4.9B |
| FY20 | $3.8B |
- Dividends
- Buybacks
Show the numbers
| Year | Dividends | Buybacks |
|---|---|---|
| FY25 | $5B | $521M |
| FY24 | $4.6B | $81M |
| FY23 | $4.5B | - |
| FY22 | $4.4B | - |
| FY21 | $3.9B | - |
| FY20 | $3.6B | - |
- AstraZeneca
- Healthcare median
Show the numbers
| Year | AstraZeneca | Healthcare median |
|---|---|---|
| FY25 | 17.4% | −30.8% |
| FY24 | 13% | −47% |
| FY23 | 13% | −58% |
| FY22 | 7.4% | −80.4% |
| FY21 | 0.3% | −71.9% |
| FY20 | 12% | −62.2% |